The global drug-device combination products market is projected to experience a compound annual growth rate (CAGR) of approximately 9% during the forecast period. This growth is largely driven by the ...
In January 2022, the U.S. Food and Drug Administration (FDA) released finalized guidance on premarket pathways for combination products. While the guidance is not binding, it provides industry ...
ST. PAUL, Minn. & ST. LOUIS--(BUSINESS WIRE)--Kindeva Drug Delivery (“Kindeva”) and Meridian Medical Technologies (“Meridian”) announced today the completion of the transaction to combine the two ...
The global drug device combination products market is expected to reach $115.1 billion by 2019, growing at a compound annual growth rate of 7.9 percent, according to a news release. In 2012, the ...
Abbott is a prominent key player in the global drug device combination products market. Abbott's Medical Devices segment delivers a combination of products, particularly in high-impact areas such as ...
Genus Medical Technologies, LLC v. FDA legal case leads to agency-wide review and reclassification of eye cups, eye droppers, and ophthalmic dispensers “While we were surprised by the FDA’s position ...
Shares of Lyra Therapeutics Inc. soared more than 310% on data from its second phase III trial testing drug-device candidate LYR-210 in patients with chronic rhinosinusitis, with results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results